Yazar "Ozdemir, Huseyin Baran" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    AN EASY WAY TO PREVENT VELOCITY-RELATED COMPLICATIONS DURING DEXAMETHASONE IMPLANT INJECTION IN VITRECTOMIZED EYES
    (Lippincott Williams & Wilkins, 2025) Ozturk, Emrah; Adam, Mehmet; Ozdemir, Huseyin Baran
    Purpose:To assess the impact of inserting an ophthalmic viscoelastic device into the dexamethasone (DEX) implant needle on pellet velocity in simulated vitrectomized eyes.Methods:Dexamethasone implants were injected into a calibrated ex vivo test chamber filled with balanced salt solution. All DEX implants were administered by the same physician, aiming for the same button depression time. In Group 1, three DEX implant injections were performed without an ophthalmic viscoelastic device, while in Group 2, the ophthalmic viscoelastic device was safely inserted into the DEX implant needle using a 27-gauge cannula just before the injection. The slow-motion video mode of the IPhone 14 was used to record the procedures and calculate time and distance measurements.Results:Group 1 exhibited a mean velocity of 450 mm/second for the DEX pellet in balanced salt solution, compared with 54.57 mm/second in Group 2. Furthermore, DEX pellets in Group 1 had horizontal displacements of 24, 29, and 31 mm, while those in Group 2 had displacements of 17, 16, and 15 mm.Conclusion:Injecting an ophthalmic viscoelastic device into the DEX implant needle significantly decreases the velocity of the free pellet in balanced salt solution by 87.87%. This modification may help prevent potential velocity-related complications linked to DEX implantation in vitrectomized eyes.
  • Küçük Resim Yok
    Öğe
    Clinical and Demographic Characteristics of Treatment Requiring Retinopathy of Prematurity in Big Premature Infants in Turkiye: Report No. 1 (BIG-ROP Study)
    (S. Karger AG, 2024) Özdek, Şengül; Ozdemir, Huseyin Baran; Ozen Tunay, Zuhal; Bayramoglu, Sadik Ekta; Alyamac Sukgen, Emine; Klr, Nur; Koç, Esin
    Introduction: The aim of the study was to analyse the clinical and demographic features of infants with gestational age (GA) of 32-37 weeks and birth weight (BW) of >1,500 g who developed treatment requiring retinopathy of prematurity (ROP). Methods: Data on the infants with a GA of 32-37 weeks and BW >1,500 g who developed treatment requiring ROP (TR-ROP) were collected retrospectively from the 33 ROP centres in Turkiye. GA, BW, type of hospital, neonatal intensive care units (NICUs) level, presence of an ophthalmologist and neonatologist in the same hospital, length of stay in NICU, duration of oxygen therapy, comorbidities, type of ROP, and timing for TR-ROP development were analysed. Results: A total of366 infants were included in the study. Mean GA and BW were 33 1 weeks and 1,896 316 g, respectively. Duration of hospitalization was 3-4 weeks in 46.8% of them. The first ROP examination was performed at postnatal 4-5 weeks in 80.3% of infants, which was significantly later in level 2 and lower NICUs and non-university clinics. At the first ROP examination, any stage of ROP was detected in 90.9% and TR-ROP was detected in 15.3% of the infants. The mean postnatal week of TR-ROP development was 6.16 2.04. Conclusion: Routine ROP screening thresholds need to be expanded in hospitals with suboptimal NICU conditions considering the development of TRROP in more mature and heavier preterm infants. The first ROP examination should be earlier than the fourth postnatal week. 2024 S. Karger AG, Basel. © 2024 S. Karger AG. All rights reserved.